Pronunciation: DOX-uh-pram HIGH-droe-KLOR-ide
- Injection 20 mg/mL
Increases depth of respirations (tidal volume) by stimulating respiratory center in CNS; respiratory rate may increase slightly. May elevate BP by increasing cardiac output. Respiratory depression from opiates is reversed without affecting pain relief.
Metabolites and a small amount of unchanged drug excreted in urine. The t ½ is 2.4 to 4.1 h.
20 to 40 sec.
1 to 2 min.
5 to 12 min.
Indications and Usage
Stimulate deep breathing in postoperative patients; reversal of respiratory depression caused by anesthesia (other than muscle relaxants) or drug overdose; temporary measure for acute respiratory failure in patients with COPD who are not undergoing mechanical ventilation.
Use in newborns (contains benzyl alcohol); seizures; muscle paresis; epilepsy or other convulsive states; flail chest; head injury; pneumothorax; acute asthma; pulmonary fibrosis; other conditions that restrict chest wall, respiratory muscles or alveolar expansion; severe hypertension; cerebrovascular accident; proven or suspected pulmonary embolism; mechanical obstruction; cerebral edema; CV impairment; uncompensated heart failure; severe coronary artery disease; hypersensitivity to any component of the product.
Dosage and AdministrationAnesthesia-induced Respiratory Depression
Max daily dose is 3 g. Bolus IV injection 0.5 to 1 mg/kg (single dose not to exceed 1.5 mg/kg). Can be given as multiple IV injections every 5 min (not to exceed total dose of 2 mg/kg).
IV infusion Initial rate 5 mg/min until satisfactory respiratory response is noted. Maintenance rate: 1 to 3 mg/min. Max total infusion dose is 4 mg/kg.Drug-induced CNS Depression
Max daily dose is 3 g. Bolus IV injection Priming dose is 1 to 2 mg/kg (mild to moderate). Repeat in 5 min. Depending on response, may give every 1 to 2 h until patient awakens. Intermittent IV infusion Priming dose is 1 to 2 mg/kg (mild to moderate). If respirations improve, give by IV infusion at 1 to 3 mg/min. Discontinue after 2 h or if patient awakens.Acute Hypercapnia from COPD
IV infusion 2 mg/mL with initial rate of 1 to 2 mg/min; may increase to max 3 mg/min; discontinue after 2 h.
Store vials at controlled room temperature (59° to 86°F).
Drug InteractionsAminophylline, theophylline
May increase skeletal muscle activity, agitation, and hyperactivity.Cyclopropane, enflurane, halothane
To prevent arrhythmias, wait at least 10 min after stopping these anesthetics before giving doxapram.MAOIs, sympathomimetics
Increased risk of hypertension.Muscle relaxants
Residual effects may be temporarily masked by doxapram.
Do not add to or give with alkaline solutions such as aminophylline, furosemide, thiopental, or sodium bicarbonate.
Laboratory Test Interactions
None well documented.
Arrhythmias; chest pain; increased BP; lowered T-waves; phlebitis; tachycardia; tightness in chest; variations in heart rate.
Apprehension; bilateral Babinski; clonus; disorientation; dizziness; hallucination; headache; hyperactivity; increased reflexes; involuntary movements; muscle spasticity and fasciculations; paresthesia; pyrexia; seizures.
Desire to defecate; diarrhea; nausea; vomiting.
Elevation of BUN; urinary incontinence and retention.
Hemolysis (with rapid infusion).
Bronchospasm; cough; dyspnea; hiccoughs; hyperventilation; laryngospasm; rebound hypoventilation; tachypnea.
Feelings of warmth; flushing; pruritus; sweating.
Category B .
Safety and efficacy not established in children younger than 12 yr of age. Doxapram contains benzyl alcohol, which has been associated with fatal gasping syndrome in premature infants.
Do not increase infusion rate in severely ill patients; drug may increase work of breathing.
Drug-induced CNS and respiratory depression
Used as adjunct to supportive care.
Do not use as antidote for opiates or neuromuscular blockers.
Severe hypertension, tachycardia, hyperactive reflexes, seizures.
- Advise patient or caregiver that medication will be prepared and administered by health care professionals in a intensive care setting with close monitoring.
Copyright © 2009 Wolters Kluwer Health.